Breaking AI & Tech News Analyzed

The explosive growth of Palantir’s AI‑driven platformSince its 2003 launch, the company founded by Peter Thiel has leveraged AI‑powered software to turn massive, complex data sets into actionable insights for governments and corporations. Its client roster now spans the NHS, the US military, ICE, and the Israeli defence forces, underpinning a valuation that has climbed to roughly $375 bn after a 1,500% stock surge since the 2020 IPO.Valuation, contracts and the £600 m UK footprint£600 m in contracts with the UK Ministry of Defence, several police forces and the NHS.£50 m Metropolitan Police deal blocked by Mayor Sadiq Khan in May 2026.Projected UK revenue growth of 30% YoY, according to internal estimates.Political and civil‑society pushback in BritainOpposition has coalesced around concerns that a US‑controlled firm is embedding itself in sovereign infrastructure. A petition signed by nearly a quarter‑million people called for the termination of all Palantir contracts, while MPs such as Martin Wrigley warned the Financial Conduct Authority’s partnership could expose sensitive data to US authorities.Data‑privacy concerns and the NHS contract controversyInvestigations revealed that Palantir gained access to un‑anonymised patient records under a £330 m NHS contract, prompting health‑justice charity Medact to warn of “data‑driven abuses of state power” and potential ICE‑style raids. Palantir maintains that any use outside client instructions would breach contract and be illegal.Future outlook: regulatory risk and competitive pressureShort‑seller Michael Burry has flagged the stock as overvalued, citing vulnerability to emerging rivals offering comparable analytics without the geopolitical baggage. If UK regulators tighten data‑sharing rules or if public procurement policies shift toward domestic providers, Palantir’s UK pipeline could face material setbacks.

FCA has begun a 12‑week trial with US data‑analytics firm Palantir to test AI‑driven crime detection, while MPs and privacy groups warn the partnership could give the Trump administration a backdoor to UK financial data under the US Cloud Act.Details of the FCA‑Palantir AI trialThe trial will see Palantir’s platforms applied to a wide range of FCA data sets, including case intelligence files, lender fraud reports, consumer complaints and social‑media monitoring. The arrangement is at the 12‑week pilot stage and is intended to improve the regulator’s ability to spot financial crime.Financial stakes and contractual backdrop$375bn valuation of Palantir, co‑founded by Trump‑supporting billionaire Peter Thiel.Palantir holds contracts worth over £500m with NHS England and the Ministry of Defence.London mayor Sadiq Khan blocked a separate £50m two‑year deal between Palantir and the Metropolitan Police.Legal and sovereignty implicationsCritics argue that under the US Cloud Act, US authorities could compel Palantir to hand over any data it processes, potentially exposing UK citizens’ financial information to US surveillance regimes such as the Patriot Act and FISA. The FCA maintains that Palantir is only a “data processor”, that all data remains encrypted, and that the regulator retains control.Potential impact on UK data policyIf the trial proceeds without robust safeguards, it could set a precedent for further reliance on US‑based AI vendors, eroding confidence in the UK’s data sovereignty and prompting stricter procurement rules. Conversely, a successful pilot could accelerate AI adoption across UK regulators, influencing future contracts with private tech firms.Outlook and next stepsParliamentary committees are expected to request a detailed legal review of the Cloud Act’s applicability. The FCA has pledged to publish trial results, but pressure from MPs like Martin Wrigley suggests additional oversight may be imposed before any wider rollout.

The Lead: A Breach of Trust in Public Health DataMPs have issued a stark warning regarding the NHS's decision to grant Palantir access to identifiable patient data, deeming the move 'dangerous' and likely to erode public confidence in data privacy standards. The controversy centers on the company's ability to view raw, non-anonymized health records before they are processed, a practice that contradicts standard security protocols.The Controversy: Access Before PseudonymizationThe core technical issue lies in the mechanism of access. Unlike standard protocols, NHS England has permitted contractors to view raw, identifiable patient records before they are anonymized. This bypasses a critical security layer, raising alarms about the potential for misuse or accidental exposure. The Federated Data Platform (FDP) was designed to integrate scattered datasets, but allowing 'unlimited access' to non-NHSE staff has triggered a significant security review.The Financial and Political StakesThe deal is valued at £330m, but the political cost is mounting. Rachael Maskell and Martin Wrigley have publicly condemned the project, while polling indicates that 40% of the UK public distrusts Palantir with sensitive health information, and two-thirds are generally concerned about the company's expanding public sector role. The company's history—supporting ICE immigration enforcement and military operations—clashes with the public's expectation of a healthcare provider.The Expanding Role of Private Tech in Public HealthThis incident is part of a broader pattern. Palantir is simultaneously negotiating with the Metropolitan Police for AI intelligence analysis. The 'cavalier attitude' cited by MPs suggests a systemic failure in 'security by design.' The Patients Association and campaign groups like Foxglove argue that patients never consented to having their data accessed by a company with a record in targeting people, not caring for them.Future Outlook: Heightened Scrutiny and Regulatory RiskGiven the intense scrutiny from both backbench MPs and the public, the project faces an uncertain future. The government will likely face increasing pressure to either halt the access to identifiable data or implement significantly stricter, auditable safeguards to restore trust. The risk of a public backlash could force a re-evaluation of how private contractors are integrated into critical national infrastructure.

Palantir’s claim that opposition to its NHS contract is driven by ideology was rebuked by Chi Onwurah, the Labour MP who chairs Parliament’s science, innovation and technology select committee. Onwurah said it is appropriate for ministers to explore a break‑clause option in the deal, underscoring the seriousness of the concerns raised. Louis Mosley, Palantir’s UK executive vice‑chair, had urged the government not to succumb to “ideologically motivated campaigners” as officials weighed a way out of a £330 million contract to deliver the Federated Data Platform (FDP) for NHS England. Ministers have now asked for advice on triggering the contract’s break clause amid growing scrutiny of Palantir’s expanding role in the public sector. The FDP is an AI‑enabled platform designed to integrate disparate health information across the NHS. Palantir already holds contracts with the Ministry of Defence, several police forces and the UK’s financial watchdog, the FCA. Onwurah’s cross‑party committee is set to publish its report in the coming weeks, covering the digital reorganisation of government services and the role of AI after a series of hearings that included experts, NHS leaders and representatives from companies such as Palantir. She identified three core issues: the manner in which the contract was awarded, the handling of patient data and the resulting trust deficit within the NHS, and the involvement of Peter Mandelson through his firm Global Counsel. “These are not fringe ideological concerns,” Onwurah told the Guardian. “They relate to contract transparency, vendor lock‑in, value for money and data security – matters that should concern everyone pushing the NHS towards digital transformation.” She added that the NHS’s post‑COVID fatigue and austerity‑driven burnout make any additional trust‑related resentment a significant barrier to progress. Onwurah noted that Palantir secured the contract after providing services to the NHS at a nominal cost – a tactic often used by large tech firms to position themselves as the most attractive government supplier. “It is right for the government to explore all options, including breaking the contract, given ongoing concerns about FDP uptake while Palantir remains at the helm,” she said. Liberal Democrat MP Martin Wrigley, also on the committee, urged the government to commission a new consortium of UK‑based tech experts to build a home‑grown NHS platform. During a previous committee appearance, Mosley accused British doctors of placing “ideology over patient interest” after they challenged the data‑processing contract. Speaking to the Times, Mosley warned that removing Palantir could jeopardise patient care and stall solutions to the NHS’s biggest challenges, arguing that the campaign against the firm would do more harm than good.